# Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg
> Note: PeptIQ is not a medical provider. Orforglipron is an investigational oral GLP-1 receptor agonist. Doses reflect Phase 3 trial designs and public disclosures — not a prescription.
Orforglipron (LY3502970) is the oral GLP-1 story people keep comparing to injectable semaglutide and tirzepatide — and to oral semaglutide's awkward fasting rules. It is a once-daily small-molecule GLP-1 receptor agonist taken as a capsule, without the food-and-water gymnastics Rybelsus requires.
Quick Answer: Orforglipron Dosage
| Phase | Dose pattern |
|---|---|
| Start | 1 mg once daily |
| Escalation | Step up about every 4 weeks |
| Obesity maintenance (ATTAIN-1) | 6 mg, 12 mg, or 36 mg once daily |
| Diabetes example (ACHIEVE-1) | Maintenance arms including 3 mg, 12 mg, 36 mg in public descriptions |
ATTAIN-1 Titration Ladder (Obesity)
ATTAIN-1 (NCT05869903) was a 72-week Phase 3 trial in adults with obesity or overweight plus comorbidity, without diabetes. Participants started at 1 mg daily and escalated at four-week intervals to their randomized maintenance dose:
| Target maintenance | Typical step path described publicly |
|---|---|
| 6 mg | 1 mg → 3 mg → 6 mg |
| 12 mg | 1 mg → 3 mg → 6 mg → 12 mg |
| 36 mg | 1 mg → 3 mg → 6 mg → 12 mg → 24 mg → 36 mg |
Dose reductions were generally reserved for GI tolerability after other mitigations failed (per public trial descriptions).
Weight-Loss Results People Cite
Public ATTAIN-1 summaries (efficacy-style figures) reported roughly:
| Arm | Approx. mean weight change @ 72 weeks |
|---|---|
| 6 mg | ~−8% |
| 12 mg | ~−9% |
| 36 mg | ~−12% |
| Placebo | ~−1% |
Treatment-policy / other estimands in media coverage sometimes quote slightly different percentages (for example ~7.5–11% ranges). Prefer the NEJM table for citations. Directionally: higher maintenance dose → larger mean loss, with classic GLP-1 GI adverse events.
Why Oral Dosing Changes Tracking
Injectable weekly drugs create a "dose day" narrative. Orforglipron is daily, which means:
- Missed-dose patterns matter more
- GI symptoms may be steadier rather than once-weekly spikes
- Adherence logging should be daily checkboxes, not only weekly entries
- No reconstitution math — but titration discipline still makes or breaks tolerability
Orforglipron vs Injectable GLP-1s
| Orforglipron | Semaglutide / tirzepatide injectables | |
|---|---|---|
| Route | Oral capsule daily | Weekly SC (mostly) |
| Food rules | No Rybelsus-style empty-stomach ritual (per public Lilly messaging) | Not applicable for injectables |
| Status | Investigational / late-stage | Multiple approved brands |
| Best SEO intent | "oral GLP-1 dosing" | "ozempic dose" / "mounjaro titration" |
What to Track
- Current daily mg and last escalation date
- Missed doses per week
- Nausea / constipation scores
- Protein grams and training
- Average weight + waist
- Reason for any dose hold
FAQ
Q: What is the highest orforglipron dose?
A: In ATTAIN-1 obesity Phase 3, the top randomized maintenance dose was 36 mg daily.
Q: Do I need to take orforglipron fasting?
A: Public Lilly communications emphasize once-daily use without the food/water restrictions required for oral semaglutide. Always follow the eventual label if approved.
Q: How fast can I titrate?
A: Trial designs used ~4-week steps. Faster DIY escalation is a common way people get knocked out by nausea.
Q: Is orforglipron a peptide?
A: It is a small-molecule GLP-1 receptor agonist (non-peptide), which is why oral bioavailability is feasible without peptide injection.
Bottom Line
Orforglipron dosing is a daily oral titration story: start 1 mg, climb every four weeks, land on 6 / 12 / 36 mg maintenance in obesity Phase 3. That ladder is the SEO asset — clear, citable, and easy to turn into a tracking template.
Download PeptIQ to log daily oral GLP-1 adherence beside body-comp trends.
Educational content only. Not medical advice.
